Genvoya is a prescription medication used for the treatment of HIV-1 infection in adults and adolescents who weigh at least 55 pounds [1]. It is a complete regimen that contains four medications in one pill [1].
What medications are in Genvoya?
Genvoya is a combination medication that includes elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1]. These four active ingredients work together to suppress the human immunodeficiency virus (HIV) [1].
How does Genvoya work to treat HIV?
The components of Genvoya target HIV in different ways. Elvitegravir is an integrase strand transfer inhibitor that blocks the enzyme integrase, which HIV needs to replicate [1]. Cobicistat is a pharmacokinetic enhancer that increases the levels of elvitegravir in the body, allowing for less frequent dosing [1]. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs) that interfere with another enzyme, reverse transcriptase, which HIV also uses to multiply [1]. By inhibiting these essential viral enzymes, Genvoya prevents the virus from replicating and spreading [1].
When was Genvoya first approved?
Genvoya was approved by the U.S. Food and Drug Administration (FDA) in November 2015 [2].
What are the potential side effects of Genvoya?
Common side effects associated with Genvoya can include nausea, diarrhea, headache, fatigue, and rash [1]. More serious side effects, though less common, can involve kidney problems and liver problems [1]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
What is the cost of Genvoya?
The cost of Genvoya can vary based on insurance coverage, pharmacy, and location [3]. Information on the drug's pricing and potential patient assistance programs can often be found through pharmaceutical manufacturer websites or patient advocacy groups [3].
Are there alternatives to Genvoya for HIV treatment?
Yes, there are other medications and treatment regimens available for HIV infection. These alternatives may include single-tablet regimens with different combinations of drugs or multi-pill regimens [4]. The choice of treatment depends on individual patient factors, including viral load, CD4 count, resistance test results, potential side effects, and co-existing medical conditions [4].
How does Genvoya compare to other HIV medications like Biktarvy?
Biktarvy is another single-tablet regimen used to treat HIV-1 infection [5]. While both Genvoya and Biktarvy are complete regimens in one pill, they contain different active ingredients [1, 5]. Biktarvy contains bictegravir, emtricitabine, and tenofovir alafenamide, whereas Genvoya contains elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1, 5]. Clinical studies have shown both regimens to be highly effective in suppressing HIV, but differences in their specific drug components can lead to varying side effect profiles and drug interaction potentials [1, 5]. Patients should consult with their doctor to determine the most appropriate medication for their individual needs [4].
What are the patent protections for Genvoya?
Genvoya, like other branded pharmaceuticals, is protected by patents that grant the manufacturer exclusive rights to sell the drug for a certain period. Information on specific patent expiry dates and potential challenges to these patents can be found on resources that track drug patents. For instance, DrugPatentWatch.com provides data on the patent status of medications like Genvoya [6]. Understanding patent timelines is crucial for anticipating the potential availability of generic versions of the drug.
When can generic versions of Genvoya become available?
The availability of generic versions of Genvoya depends on the expiry of its patents and any regulatory exclusivities [6]. Once these protections expire and if no further legal challenges or extensions are in place, other companies may apply to the FDA to market generic versions of the drug [6]. This process can take time and is subject to regulatory review.
---
Sources
[1] https://www.genvoya.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/novel-drug-approvals-2015
[3] https://www.goodrx.com/genvoya
[4] https://www.aids.gov/federal-response/policy-initiatives/hiv-aids-care-connect/
[5] https://www.biktarvy.com/
[6] https://drugpatentwatch.com/